On October 28, 2019, Ascentage Pharma Group International (Ascentage Pharma), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus, and age-related diseases, completed its initial public offering and listing on the Main Board of the Stock Exchange of Hong Kong, raising HK$416 million after issuing 12,180,900 shares at HK$34.20 per share, the high end of the price range. Its public offering tranche was more than 750 times over-subscribed, making it the most over-subscribed IPO stock in Hong Kong this year. Ascentage is the tenth pre-revenue biotech company listed on the Hong Kong Stock Exchange.

Wilson Sonsini Goodrich & Rosati acted as the Hong Kong counsel to Ascentage Pharma. The team representing Ascentage Pharma was led by Wilson Sonsini partner Weiheng Chen.

For more information, please see a Bloomberg report on the listing.